Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors
- 1st Edition, Volume 95 - November 20, 2010
- Latest edition
- Editor: Erkki Nissinen
- Language: English
Volume 95 of International Review of Neurobiology focuses on Catechol-O-methyltransferase inhibition, and its clinical application in relation to Parkinson’s disease. Chapte… Read more
Purchase options
Description
Description
Volume 95 of International Review of Neurobiology focuses on Catechol-O-methyltransferase inhibition, and its clinical application in relation to Parkinson’s disease. Chapters cover COMT gene and proteins, L-dopa treatment in Parkinson’s disease, the latest research on COMT inhibitors and their clinical applications, as well as future prospects for their use.
Key features
Key features
- Up-to-date summary of biochemistry and pharmacology of COMT and its inhibitors
- Preclinical models in COMT inhibitor devlopment
- Transgenic COMT mice – latest information summarized
- Chemistry of COMT inhibitors and their design with molecular modelling
- COMT gene and its regulation and relation to dopamine related diseases
- Role of cofactor SAM regulation in relation to homocysteine
- Nonclinical and clinical safety of COMT inhibitors summarized
- Future prospects of COMT inhibitors in Parkinson’s disease
Readership
Readership
Neuroscientists, neurologists, psychologists
Table of contents
Table of contents
- Introductory remarks: Catechol-O-methyltransferase inhibition: an innovative approach to enhance L-dopa therapy in Parkinson’s disease with dual enzyme inhibition
- The catechol-O-methyltransferase gene, its regulation and polymorphisms
- Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture?
- Catechol-O-methyltransferase enzyme: Cofactor S-adenosyl-L-methionine and related mechanisms
- Biochemistry and pharmacology of catechol-O-methyltrasferase inhibitors
- The Chemistry of Catechol-O-methyltransferase Inhibitors
- Toxicology and safety of COMT inhibitors
- Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of the L-dopa treatment
- Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease
- Catechol-O-methyltransferase and pain
Erkki Nissinen
Elizabeth M. Tunbridge
Timo T. Myöhänen & Pekka T. Männistö
Thomas Müller
Erkki Nissinen and Pekka T. Männistö
David A. Learmonth, László E. Kiss and Patrício Soares-da-Silva
Kristiina Haasio
Concepció Marin, J.A. Obeso
Seppo Kaakkola
Oleg Kambur & Pekka T. Männistö
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 95
- Published: November 20, 2010
- Language: English
About the editor
About the editor
Erkki Nissinen
Series Volume Editor
Affiliations and expertise
Orion Corporation, Espoo, FinlandView book on ScienceDirect
View book on ScienceDirect
Read Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors on ScienceDirect